Dr. Nina Maouelainin shares a case where Percepta GSC up-classified the risk of lung cancer guiding the next intervention step, and Envisia determined a UIP pattern to improve ILD diagnostic confidence, guiding management using a non-invasive bronchoscopy.
Veracyte representatives are happy to assist you and to discuss how to integrate our tests into your practice. Monday-Friday, 5:30AM - 5PM (Pacific Time)
6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
+1.844.464.5864 Office
+1.650.243.6335 Fax
The Percepta Genomic Sequencing Classifier (GSC) is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.
This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.
© 2023 Veracyte, Inc. All rights reserved.
Offices
6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
163 Avenue de Luminy
13009 Marseille
FRANCE
6925 Lusk Boulevard, Suite 200
San Diego, CA 92121
12357-A Riata Trace Parkway
Building 5, Suite 100
Austin, TX 78727
Connect
